Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
North China Pharmaceutical Company.Ltd Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 1/6
North China Pharmaceutical Company.Ltd has a total shareholder equity of CN¥6.6B and total debt of CN¥11.2B, which brings its debt-to-equity ratio to 170.5%. Its total assets and total liabilities are CN¥21.8B and CN¥15.2B respectively. North China Pharmaceutical Company.Ltd's EBIT is CN¥566.3M making its interest coverage ratio 1.4. It has cash and short-term investments of CN¥1.8B.
Anahtar bilgiler
170.5%
Borç/özkaynak oranı
CN¥11.17b
Borç
| Faiz karşılama oranı | 1.4x |
| Nakit | CN¥1.77b |
| Eşitlik | CN¥6.55b |
| Toplam yükümlülükler | CN¥15.20b |
| Toplam varlıklar | CN¥21.75b |
Son finansal sağlık güncellemeleri
Güncelleme yok
Recent updates
Benign Growth For North China Pharmaceutical Company.Ltd (SHSE:600812) Underpins Its Share Price
Sep 25
North China Pharmaceutical Company.Ltd's (SHSE:600812) Profits Appear To Have Quality Issues
Aug 20The Market Doesn't Like What It Sees From North China Pharmaceutical Company.Ltd's (SHSE:600812) Revenues Yet
Apr 26Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: 600812's short term assets (CN¥8.8B) do not cover its short term liabilities (CN¥11.4B).
Uzun Vadeli Yükümlülükler: 600812's short term assets (CN¥8.8B) exceed its long term liabilities (CN¥3.8B).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: 600812's net debt to equity ratio (143.5%) is considered high.
Borcun Azaltılması: 600812's debt to equity ratio has increased from 152.7% to 170.5% over the past 5 years.
Borç Kapsamı: 600812's debt is not well covered by operating cash flow (14.7%).
Faiz Kapsamı: 600812's interest payments on its debt are not well covered by EBIT (1.4x coverage).